To add to my previous video link, leronlimab was developed to cover 108% of the specific portion of the CCR5 receptor where HIV binds. Fortunately, this also seems to be the portion of the CCR5 receptor that calcium signaling occurs that appears to play important roles in cancer metastasis, immune modulating responses and cell migration that could impact COVID, ARDS and a host of other immunological disorders (see Ohm potential indication list).

I also recommend the two tagged posts by trding (when viewing from a computer). He spent a lot of time researching and compiling this information that should be a must read for investor or physician trying to learn more about leronlimab or the general science behind CCR5.

https://investorshangout.com/post/view?id=5627230
https://investorshangout.com/post/view?id=5506865


This is also a must read IMO: The Expanding Therapeutic Perspective of CCR5 Blockade
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5770570/